PDS Biotechnology Investor Relations Material
Latest events
Q4 2023
PDS Biotechnology
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from PDS Biotechnology Corporation
Access all reports
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its product pipeline includes thermo-sensitive PDS0101 (Amiket), which is in Phase 3 clinical trials for the treatment of patients with human papillomavirus associated disease; Discovery Program, a research and discovery program with a focus on tumor neo-antigens and synthetic vaccines; and Thermo-Oxidative Stress Induced Antigen(TOSIA) Program that combines chemical engineering, molecular biology, and immunology to discover tumor associated antigens.
Key slides for PDS Biotechnology Corporation
Study Update
PDS Biotechnology Corporation
Study Update
PDS Biotechnology Corporation
Latest articles
Four Decades of IPOs: An Overview
An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.
24 Apr 2024
Larry Page: The Mastermind Behind Google
Explore the journey of Larry Page from a tech-savvy youth to co-founding Google and leading Alphabet.
24 Apr 2024
Mark Leonard: The Mysterious Brain Behind Constellation Software
Information about Mark Leonard is scarce, and one of the only ways to “get to know” him is through his shareholder letters. Join us in an attempt to do so.
24 Apr 2024
Ticker symbol
Country
🇺🇸 United States